A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors

1990 ◽  
Vol 26 (5) ◽  
pp. 343-344 ◽  
Author(s):  
Peter C. Adamson ◽  
Solomon Zimm ◽  
Abdel H. Ragab ◽  
Seth M. Steinberg ◽  
Frank Balis ◽  
...  
Keyword(s):  
Continuous Infusion ◽  
Solid Tumors ◽  
Phase Ii ◽  
Phase Ii Trial

Phase II trial of indicine N-oxide in relapsed pediatric solid tumors

1991 ◽  
Vol 9 (4) ◽  
Author(s):  
JamesS. Miser ◽  
WilliamA. Smithson ◽  
William Krivit ◽  
Carla Hughes ◽  
Dianne Davis ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Pediatric Solid Tumors

4?-Epi-doxorubicin ? A clinical phase-II trial in solid tumors

1984 ◽  
Vol 107 (1) ◽  
pp. 38-41 ◽  
Author(s):  
J. Sch�tte ◽  
N. Niederle ◽  
B. Grunenberg ◽  
W. Krischke ◽  
S. Seeber ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Clinical Phase

A phase II trial of topotecan and radiation therapy for CNS-metastases of patients with solid tumors

2001 ◽  
Vol 37 ◽  
pp. S345-S346
Author(s):  
J. Hedde ◽  
Y. Ko ◽  
U. Metzler ◽  
H. Vetter ◽  
I. Schmidt-Wolff ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Solid Tumors ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Cns Metastases

A phase II trial of continuous-infusion 5-fluorouracil, mitoxantone and cisplatin for metastatic hepatocellular carcinoma

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 4081-4081
Author(s):  
M. Ikeda ◽  
T. Okusaka ◽  
H. Ueno ◽  
Y. Takezako ◽  
C. Morizane
Keyword(s):  
Hepatocellular Carcinoma ◽  
Continuous Infusion ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Metastatic Hepatocellular Carcinoma

A phase II trial of irinotecan, 5-fluorouracil and leucovorin in patients with previously untreated advanced colorectal cancer (CRC)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 14599-14599
Author(s):  
N. Lee ◽  
S. Bae ◽  
S. Lee ◽  
D. Kim ◽  
K. Kim ◽  
...  
Keyword(s):  
Continuous Infusion ◽  
Phase Ii ◽  
Response Rate ◽  
Phase Ii Trial ◽  
Performance Status ◽  
Objective Response ◽  
Tumor Control ◽  
Ecog Performance Status ◽  
Grade 3 ◽  
Ecog Ps

14599 Background: We prospectively conducted a phase II trial to test the efficacy and safety of irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) regimens for the first-line treatment of previously untreated patients with recurrent or metastatic advanced CRC. Methods: Thirty-four previously untreated patients with advanced CRC were enrolled in this study from June 2001 to December 2006. Eligible patients had histologically confirmed adenocarcinoma, no prior systemic therapy in palliative setting, ECOG PS = 2, adequate organ function, written informed consent and at least one measurable disease. The patients received either irinotecan 180 mg/m2 on day 1 with a LV bolus of 200 mg/m2 and a FU bolus of 400 mg/m2, and this was followed by a FU continuous infusion of 600 mg/m2 on day 1 and day 2 (the classic FOLFIRI regimen), or they were treated with a LV bolus of 400 mg/m2 and a FU bolus of 400 mg/m2 followed by a FU continuous infusion of 2,400 mg/m2 for 46 hours (the simplified FOLFIRI regimen), and these treatments were repeated every 2 weeks until disease progression. Results: There were 13 females and 21 males with median age of 54 years (range: 41–79). The most common metastatic sites were lung and liver. A total of 262 cycles were administrated with median 6 cycles per patient (range: 1–22). All pts were evaluable for toxicity, and 30 pts for response to the treatment. The objective response rate was 26.4% with 2 complete responses respectively. Sixteen (47%) pts had stable disease and 7 (20.5%) had a progression. The tumor control rate was 73.4%. The median TTP was 5.3 months, and the overall survival was 10.1 months. The prognostic factor for longer TTP and survival was the ECOG performance status (PS). The type of regimens was not affected on response rate, TTP and survival. The chemotherapy was generally well tolerated and the most common grade 3–4 toxicities were neutropenia, diarrhea. The non- hematological toxicities were similar for both treatment groups, with more frequent grade =3 neutropenia being noted for the simplified FOLFIRI regimen. Conclusions: The FOLFIRI regimen was demonstrated to have a moderate antitumor activity with acceptable toxicity profiles, and tend to show more favorable outcome for patients with good ECOG PS. No significant financial relationships to disclose.

Phase II Trial of Topotecan Administered as a 21-Day Continuous Infusion in Previously Untreated Patients With Stage IIIB and IV Non-Small-Cell Lung Cancer

1998 ◽  
Vol 21 (5) ◽  
pp. 438-441 ◽  
Author(s):  
Hedy L. Kindler ◽  
Mark G. Kris ◽  
Ian E. Smith ◽  
Vincent A. Miller ◽  
Stefan C. Grant ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Continuous Infusion ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Phase Ii Trial ◽  
Small Cell ◽  
Stage Iiib ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document